Insider Buying: Evolus, Inc. (NASDAQ:EOLS) Director Acquires 20,000 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) Director Albert G. White III acquired 20,000 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were acquired at an average price of $9.45 per share, with a total value of $189,000.00. Following the acquisition, the director now owns 50,378 shares in the company, valued at approximately $476,072.10. The trade was a 65.84% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Evolus Price Performance

Shares of NASDAQ:EOLS traded down $0.17 during midday trading on Friday, reaching $10.01. 343,178 shares of the company's stock traded hands, compared to its average volume of 937,124. The company has a fifty day simple moving average of $10.30 and a two-hundred day simple moving average of $11.82. Evolus, Inc. has a 1 year low of $8.67 and a 1 year high of $17.82. The company has a market cap of $645.47 million, a P/E ratio of -11.03 and a beta of 1.00. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on EOLS shares. Barclays increased their price objective on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Evolus in a research report on Thursday, May 8th. BTIG Research initiated coverage on Evolus in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective for the company. Finally, HC Wainwright reissued a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $23.75.

Institutional Trading of Evolus

A number of institutional investors have recently made changes to their positions in EOLS. Rhumbline Advisers grew its holdings in shares of Evolus by 4.1% during the first quarter. Rhumbline Advisers now owns 83,436 shares of the company's stock worth $1,004,000 after buying an additional 3,287 shares in the last quarter. Jane Street Group LLC boosted its position in Evolus by 484.8% during the first quarter. Jane Street Group LLC now owns 69,947 shares of the company's stock worth $841,000 after acquiring an additional 57,987 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Evolus by 36.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company's stock valued at $1,883,000 after acquiring an additional 41,513 shares in the last quarter. Zimmer Partners LP raised its holdings in Evolus by 21.2% in the 1st quarter. Zimmer Partners LP now owns 505,000 shares of the company's stock valued at $6,075,000 after acquiring an additional 88,500 shares during the last quarter. Finally, Jones Financial Companies Lllp purchased a new position in Evolus during the first quarter worth approximately $158,000. 90.69% of the stock is owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.